Business Description
Ascelia Pharma AB
ISIN : SE0010573113
Total Employee Number:
10Compare
Compare
Traded in other countries / regions
ACE.SwedenACEs.UK7ZA.Germany IPO Date
2019-09-27Description
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 49.18 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37 | |||||
3-Year EPS without NRI Growth Rate | 35.9 | |||||
3-Year FCF Growth Rate | 36.5 | |||||
3-Year Book Growth Rate | -40.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-1 Month Momentum % | -92.7 | |||||
6-1 Month Momentum % | -92.7 | |||||
12-1 Month Momentum % | -92.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.8 | |||||
Quick Ratio | 2.8 | |||||
Cash Ratio | 2.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.6 | |||||
Shareholder Yield % | -11.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.07 | |||||
ROA % | -59.73 | |||||
ROIC % | -85.15 | |||||
3-Year ROIIC % | -654.64 | |||||
ROC (Joel Greenblatt) % | -6262.73 | |||||
ROCE % | -75.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 13.16 | |||||
PB Ratio | 4.71 | |||||
Price-to-Tangible-Book | 15.67 | |||||
EV-to-EBIT | -5.53 | |||||
EV-to-EBITDA | -5.53 | |||||
EV-to-FCF | -5.31 | |||||
| Price-to-Net-Current-Asset-Value | 15.67 | |||||
| Price-to-Net-Cash | 19.35 | |||||
Earnings Yield (Greenblatt) % | -18.08 | |||||
FCF Yield % | -17.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascelia Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.59 | ||
| Beta | 0.1896 | ||
| 3-Year Sharpe Ratio | -0.66 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 92.7 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (kr) | 0.503733 | ||
| 20-Day SMA (kr) | 3.29 | ||
| 12-1 Month Momentum % | -92.7 | ||
| 52-Week Range (kr) | 3.29 - 45.05 | ||
| Shares Outstanding (Mil) | 133.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascelia Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascelia Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 52 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 52 days | ||
| First quarter earnings conference call for 2026 | 2026-05-12 10:00 | 45.05 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 45.05 (+0.00%) | ||
| General meeting for 2026 | 2026-05-04 14:00 | 45.05 (+0.00%) | ||
| Annual report for 2025 | 2026-04-09 | 45.05 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-06 13:00 | 45.05 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-05 | 45.05 (+0.00%) |
Show
Entries
Ascelia Pharma AB Frequently Asked Questions
What is Ascelia Pharma AB(CHIX:ACEs)'s stock price today?
The current price of CHIX:ACEs is kr3.29. The 52 week high of CHIX:ACEs is kr45.05 and 52 week low is kr3.29.
When is next earnings date of Ascelia Pharma AB(CHIX:ACEs)?
The next earnings date of Ascelia Pharma AB(CHIX:ACEs) is 2026-08-20.
Does Ascelia Pharma AB(CHIX:ACEs) pay dividends? If so, how much?
Ascelia Pharma AB(CHIX:ACEs) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ascelia Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers